Literature DB >> 3971122

R2/3 gastrectomy for gastric carcinoma: an audited experience of a consecutive series.

R T Diggory, A Cuschieri.   

Abstract

A consecutive series of 27 patients with gastric neoplasm (24 carcinoma, 3 lymphoma) have been staged at laparotomy using the Japanese criteria for macroscopic staging. In 20 patients the radical R2/3 resection was considered potentially curative as defined by the Japanese Society for Research in Gastric Cancer. The operative mortality in this subgroup was 1/20 (5 per cent) and 3/27 (11 per cent) in the entire series. Locoregional recurrence was not observed in the potentially curative group. Follow-up has varied from 6 months to 7 years. An overall survival of 12/27 (48 per cent) has been observed to date. Death from cancer dissemination is maximal in the first and second year after resection. The R2/3 resection was considered non-curative in seven patients. In this subgroup there were two postoperative deaths and four have died of metastatic disease within 12 months of the resection. The only 5 year survivor in this group had a gastric lymphoma.

Entities:  

Mesh:

Year:  1985        PMID: 3971122     DOI: 10.1002/bjs.1800720226

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  9 in total

1.  Lymph node metastases of gastric cancer. General pattern in 1931 patients.

Authors:  K Maruyama; P Gunvén; K Okabayashi; M Sasako; T Kinoshita
Journal:  Ann Surg       Date:  1989-11       Impact factor: 12.969

2.  Programme for early detection of gastric cancer.

Authors:  P W Houghton; I D Stewart; N J Mortensen; R C Williamson
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-04

3.  Long-term survival in Japanese patients with far advanced carcinoma of the stomach.

Authors:  D Korenaga; S Tsujitani; M Haraguchi; T Okamura; R Tamada; K Sugimachi; K Akazawa; Y Nose
Journal:  World J Surg       Date:  1988-04       Impact factor: 3.352

4.  Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy.

Authors:  M Lise; D Nitti; A Marchet; T Sahmoud; N Duez; A Fornasiero; J G dos Santos; R Labianca; P Lasser; M Gignoux
Journal:  Ann Surg Oncol       Date:  1995-11       Impact factor: 5.344

5.  A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer.

Authors:  C S Robertson; S C Chung; S D Woods; S M Griffin; S A Raimes; J T Lau; A K Li
Journal:  Ann Surg       Date:  1994-08       Impact factor: 12.969

6.  Curative surgery for gastric cancer: study of 166 consecutive patients.

Authors:  J C de Almeida; A Bettencourt; C S Costa; J M de Almeida
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352

7.  Lymphangitis carcinomatosis of the lesser omentum: a prognostic factor in gastric cancer.

Authors:  G Wetscher; E Bodner; E Redmond; G Perdikis; M Gadenstätter; P Klingler; R Pointner
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

8.  Rationale for extensive lymphadenectomy in early gastric carcinoma.

Authors:  K Miwa; I Miyazaki; H Sahara; T Fujimura; Y Yonemura; M Noguchi; R Falla
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

Review 9.  Changing Trends in Gastric Cancer Surgery.

Authors:  İlter Özer; Erdal Birol Bostancı; Murat Ulaş; Yusuf Özoğul; Musa Akoğlu
Journal:  Balkan Med J       Date:  2017-01-05       Impact factor: 2.021

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.